Should I buy or sell Design Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares. View DSGN analyst ratings or view top-rated stocks .

What is Design Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 1-year price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price. View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts .

How have DSGN shares performed in 2023?

Design Therapeutics' stock was trading at $10.26 at the beginning of the year. Since then, DSGN shares have decreased by 76.1% and is now trading at $2.45. View the best growth stocks for 2023 here .

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024. View our DSGN earnings forecast .

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.14.

What ETFs hold Design Therapeutics' stock?

ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) . iShares Neuroscience and Healthcare ETF (IBRN) .

When did Design Therapeutics IPO?

(DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (4.49%), Principal Financial Group Inc. (1.28%), Walleye Capital LLC (0.67%), Assenagon Asset Management S.A. (0.44%), Prescott Group Capital Management L.L.C. (0.32%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Arsani William , Deepa Prasad, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu. View institutional ownership trends .

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Design Therapeutics Stock Price, News & Analysis (NASDAQ:DSGN)

$2.45

+0.01 (+0.41%)

(As of 12/6/2023 ET)

Compare

Today's Range: $2.42
▼
$2.51
50-Day Range: $1.99
▼
$2.51
52-Week Range: $1.94
▼
$13.94

Volume: 426,261 shs
Average Volume: 534,557 shs
Market Capitalization: $137.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 131.3% Upside
$5.67 Price Target
Short Interest: Bearish
9.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$49,350 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.30) to ($1.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

586th out of 955 stocks

Pharmaceutical Preparations Industry

244th out of 402 stocks

3.0

Analyst's Opinion

Consensus Rating
Design Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.67, Design Therapeutics has a forecasted upside of 131.3% from its current price of $2.45.
Amount of Analyst Coverage
Design Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.61% of the float of Design Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Design Therapeutics has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Design Therapeutics has recently increased by 0.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Design Therapeutics does not currently pay a dividend.
Dividend Growth
Design Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DSGN.

1.1

News and Social Media Coverage

Search Interest
2 people have searched for DSGN on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Design Therapeutics to their MarketBeat watchlist in the last 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Design Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,350.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
25.70% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.47% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Design Therapeutics are expected to decrease in the coming year, from ($1.30) to ($1.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Design Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Design Therapeutics is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Design Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DSGN Stock News Headlines

November 25, 2023 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

November 16, 2023 | markets.businessinsider.com

Hold Rating on Design Therapeutics Amid Mixed Efficacy Data, Strategic Realignment and Financial Uncertainties

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 14, 2023 | finance.yahoo.com

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

November 13, 2023 | finance.yahoo.com

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

September 8, 2023 | fool.com

Design Therapeutics (NASDAQ: DSGN)

September 7, 2023 | benzinga.com

Director At This Health Care Company Buys $14.00M of Stock

August 23, 2023 | finance.yahoo.com

Why Shares of Design Therapeutics Are Plummeting on Tuesday

December 6, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

August 16, 2023 | markets.businessinsider.com

Why Is Design Therapeutics Stock Moving Lower Today?

August 15, 2023 | msn.com

Wedbush cuts Design Therapeutics to neutral, cites ataxia drug setback

August 15, 2023 | msn.com

Multiple Downgrades Send Design Therapeutics (NASDAQ:DSGN) Down in Flames

August 15, 2023 | msn.com

RBC Capital cuts Design Therapeutics to sector perform, cites limited catalysts

August 15, 2023 | markets.businessinsider.com

Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments

August 15, 2023 | msn.com

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

August 14, 2023 | finance.yahoo.com

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

August 14, 2023 | finance.yahoo.com

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

August 4, 2023 | markets.businessinsider.com

Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)

July 19, 2023 | finance.yahoo.com

DSGN - Design Therapeutics, Inc.

July 6, 2023 | msn.com

Design Therapeutics (DSGN) Price Target Increased by 18.30% to 27.03

June 18, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

June 18, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \

May 31, 2023 | finance.yahoo.com

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 18, 2023 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Design Therapeutics (DSGN)

May 12, 2023 | msn.com

Wedbush Maintains Design Therapeutics (DSGN) Outperform Recommendation

May 12, 2023 | marketwatch.com

Types of Applications Driving Digital Therapeutics Market Growth: An Overview

May 12, 2023 | msn.com

RBC Capital Maintains Design Therapeutics (DSGN) Outperform Recommendation

See More Headlines

Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DSGN
CUSIP: N/A
CIK: 1807120
Web: www.designtx.com
Phone: 858-293-4900
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.67
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +128.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,310,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.69%
Return on Assets: -22.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.77
Quick Ratio: 23.77

Sales & Book Value

Annual Sales: $230,000.00
Price / Sales: 603.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.85 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 56,002,000
Free Float: 41,609,000
Market Cap: $138.88 million
Optionable: Not Optionable
Beta: 1.62

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Pratik Shah Ph.D. (Age 53)
Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Comp: $638.46k
Dr. Sean Jeffries Ph.D. (Age 43)
Chief Operating Officer
Comp: $572.21k
Dr. Aseem Z. Ansari Ph.D.
Co-Founder & Scientific Advisor
Ms. Julie D. Burgess CPA
Chief Accounting Officer
Dr. Elizabeth Gordon Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Jae B. Kim FACC (Age 53)
M.D., Chief Medical Officer
Ms. Dawn Giangiulio
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings or view top-rated stocks.
What is Design Therapeutics' stock price target for 2024?: 7 Wall Street research analysts have issued 1-year price objectives for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 131.3% from the stock's current price.
View analysts price targets for DSGN or view top-rated stocks among Wall Street analysts.
How have DSGN shares performed in 2023?: Design Therapeutics' stock was trading at $10.26 at the beginning of the year. Since then, DSGN shares have decreased by 76.1% and is now trading at $2.45.
View the best growth stocks for 2023 here.
When is Design Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our DSGN earnings forecast.
How were Design Therapeutics' earnings last quarter?: Design Therapeutics, Inc. (NASDAQ:DSGN) released its quarterly earnings data on Monday, November, 13th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.42) by $0.14.

What ETFs hold Design Therapeutics' stock?: ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN).
When did Design Therapeutics IPO?: (DSGN) raised $228 million in an IPO on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.
Who are Design Therapeutics' major shareholders?: Design Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RTW Investments LP (4.49%), Principal Financial Group Inc. (1.28%), Walleye Capital LLC (0.67%), Assenagon Asset Management S.A. (0.44%), Prescott Group Capital Management L.L.C. (0.32%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends.
How do I buy shares of Design Therapeutics?: Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Design Therapeutics Stock Price, News & Analysis (NASDAQ:DSGN)

Design Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Design Therapeutics Stock (NASDAQ:DSGN)

DSGN Stock Price History

DSGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DSGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™